Literature DB >> 17297449

Transgenic expression of human thymidylate synthase accelerates the development of hyperplasia and tumors in the endocrine pancreas.

M Chen1, L Rahman, D Voeller, E Kastanos, S X Yang, L Feigenbaum, C Allegra, F J Kaye, P Steeg, M Zajac-Kaye.   

Abstract

Thymidylate synthase (TS) is an essential enzyme for DNA synthesis and repair and elevated levels of TS have been identified as an important prognostic biomarker for colorectal cancer and several other common human malignancies. In addition, TS gene expression has been linked with cell-cycle regulation and cell proliferation through the ability of retinoblastoma protein to repress the transcriptional activation of E2F target genes such as TS. Therefore, overproduction of TS could participate in the progression to a neoplastic phenotype. Consistent with this model, a recent study has suggested that ectopic TS expression can induce a transformed phenotype in mammalian cells. To investigate the role of deregulated TS activity in tumor development, we generated transgenic mice that express high levels of catalytically active human TS (hTS) exclusively in the pancreas and low levels of hTS in multiple other tissues. Analyses of pancreatic tissue in TS transgenic mice revealed abnormalities within the endocrine pancreas, ranging from pancreatic islet hyperplasia to the detection of islet cell tumors. Overexpression of hTS in murine islets provides a new model to study genetic alterations associated with the progression from normal cells to hyperplasia to islet cell tumors, and suggests that this mouse model may be useful for regulating TS activity in vivo for development of cancer prevention and new therapies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17297449     DOI: 10.1038/sj.onc.1210273

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  7 in total

Review 1.  Metabolic genes in cancer: their roles in tumor progression and clinical implications.

Authors:  Eiji Furuta; Hiroshi Okuda; Aya Kobayashi; Kounosuke Watabe
Journal:  Biochim Biophys Acta       Date:  2010-02-01

Review 2.  Nucleotide metabolism, oncogene-induced senescence and cancer.

Authors:  Katherine M Aird; Rugang Zhang
Journal:  Cancer Lett       Date:  2014-01-29       Impact factor: 8.679

3.  Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms.

Authors:  Xia Xu; Jennifer L Page; Jennifer A Surtees; Houchun Liu; Sarah Lagedrost; Young Lu; Roderick Bronson; Eric Alani; Alexander Yu Nikitin; Robert S Weiss
Journal:  Cancer Res       Date:  2008-04-15       Impact factor: 12.701

Review 4.  Replication stress and cancer.

Authors:  Hélène Gaillard; Tatiana García-Muse; Andrés Aguilera
Journal:  Nat Rev Cancer       Date:  2015-05       Impact factor: 60.716

5.  Integrated analysis of competitive endogenous ribose nucleic acids (ceRNAs)-related regulatory networks in invasive and non-invasive non-functioning pituitary adenomas (NFPAs).

Authors:  Jiangtao Liu; Kaixuan Wang; Hongming Ji; Gangli Zhang; Shengli Chen; Shiyuan Zhang; Fake Lu; Changchen Hu
Journal:  Front Surg       Date:  2022-09-29

6.  Effects of small interfering RNA targeting thymidylate synthase on survival of ACC3 cells from salivary adenoid cystic carcinoma.

Authors:  Takashi Shirasaki; Shin-ichiro Maruya; Hiroki Mizukami; Seiji Kakehata; Hidekachi Kurotaki; Soroku Yagihashi; Hideichi Shinkawa
Journal:  BMC Cancer       Date:  2008-11-26       Impact factor: 4.430

7.  Targeting Thymidylate Synthase Enhances the Chemosensitivity of Triple-Negative Breast Cancer Towards 5-FU-Based Combinatorial Therapy.

Authors:  Nair Hariprasad Haritha; Akbar Nawab; Vinod Vijayakurup; Nikhil Ponnoor Anto; Vijayasteltar B Liju; Vijai V Alex; Areekkara Nisthul Amrutha; Sreekumar U Aiswarya; Mundanattu Swetha; Balachandran S Vinod; Sankar Sundaram; Maria V Guijarro; Thomas Herlevich; Archana Krishna; Nesteena K Nestory; Smitha V Bava; Chittalakkottu Sadasivan; Maria Zajac-Kaye; Ruby John Anto
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.